![[Podcast] Behind the Breakthroughs: How Almac Powers Clinical Trial Success with Care](https://imgproxy.divecdn.com/5lAJkli_KcGt1FSsw4EaegjgP76IHREqYEWbhNBJOXw/g:ce/rs:fit:770:435/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9CaW9QaGFybWFEaXZlXzEzNDZfeF83MjlfQXJ0d29yay5qcGc=.webp)
![Video: Marine Serre on Building an Independent Label [English]](https://r.fashionunited.com/LqmL4gcTYaW-0R1pmasQw2Q6yxCrLLvNKSMy3RmjiQg/resize:fit:1200:630:0/gravity:ce/quality:70/aHR0cHM6Ly9mYXNoaW9udW5pdGVkLmNvbS9pbWcvdXBsb2FkLzIwMjUvMDQvMDQvbWFyaW5lLXNlcnJlLW0tczI0LTAzMC16em01bWVqYi0yMDIzLTA4LTIwLXBkNnpmbzc4LTIwMjUtMDQtMDQuanBlZw.jpeg)
.jpg)
Roche looks to a Flagship startup in search of new immune drugs
Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech division unearth T-cell targeting therapies for inflammatory diseases.
Repertoire Immune Medicines will get $35 million upfront, and possibly $730 million more, in a deal to help Roche’s Genentech division unearth T-cell targeting therapies for inflammatory diseases.
